Tonix Pharmaceuticals Holding Corp.(TNXP)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Tonix Pharmaceuticals Holding Corp. (TNXP) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TNXP at 26.5/100 on a 32-signal composite quality model, placing it at rank #2,617 of 2,960 stocks — the bottom half of the AI-ranked universe. TNXP scores in the top quartile across institutional flow (95.6), revenue growth (91.6). Areas of concern include balance sheet strength (2.0) and free cash flow (2.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Tonix Pharmaceuticals Holding Corp. reports quarterly revenue of $13.5M, net income of $-40.6M, free cash flow of $-42.8M. Top institutional holders of TNXP by reported 13-F value include BlackRock, Point72 Asset Management, L.P., MILLENNIUM MANAGEMENT, based on the most recent SEC filings. TNXP trades on the Nasdaq exchange and files with the SEC under CIK 1430306. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TNXP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Tonix Pharmaceuticals Holding Corp. directly from SEC EDGAR.